<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001060</url>
  </required_header>
  <id_info>
    <org_study_id>DATRI 101</org_study_id>
    <secondary_id>11741</secondary_id>
    <secondary_id>DATRI 0101</secondary_id>
    <nct_id>NCT00001060</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons</brief_title>
  <official_title>A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lederle-Praxis Biologicals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety of immunization with HIV-1 C4-V3 polyvalent peptide vaccine in&#xD;
      HIV-infected persons. To determine the proportion of study participants immunized who develop&#xD;
      new specificities or increased levels of neutralizing and other antibody responses, T-cell&#xD;
      proliferative responses, and Class I restricted cytotoxic T-lymphocyte ( CTL ) responses.&#xD;
&#xD;
      HIV-1 C4-V3 polyvalent peptide vaccine contains amino acid sequences for selected epitopes&#xD;
      from four of the most common HIV isolates in the United States and Europe, predicted to&#xD;
      represent about 50-90 percent of the HIV isolates in the United States. It includes epitopes&#xD;
      that generate potentially salutary immune responses and deletes epitopes that generate immune&#xD;
      responses which might contribute to further immunopathogenesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 C4-V3 polyvalent peptide vaccine contains amino acid sequences for selected epitopes&#xD;
      from four of the most common HIV isolates in the United States and Europe, predicted to&#xD;
      represent about 50-90 percent of the HIV isolates in the United States. It includes epitopes&#xD;
      that generate potentially salutary immune responses and deletes epitopes that generate immune&#xD;
      responses which might contribute to further immunopathogenesis.&#xD;
&#xD;
      Patients are randomized to receive low-dose or high-dose HIV-1 C4-V3 polyvalent peptide&#xD;
      vaccine in incomplete Freund's adjuvant (IFA), or IFA alone as control. Injections are&#xD;
      administered on day 0 and at weeks 4, 8, 12, and 24. When patients entered at the lower&#xD;
      vaccine dose (Cohort A) reach week 6, the data is reviewed and the higher dose cohort (Cohort&#xD;
      B) will begin. When both cohorts reach week 14, data is evaluated and Cohort C begins vaccine&#xD;
      administrations at a chosen vaccine dose. Within each cohort, eight patients receive vaccine&#xD;
      plus IFA and two patients receive IFA alone. Patients are followed to week 52; 18 clinic&#xD;
      visits and four telephone calls are required.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">June 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 C4-V3 Polyvalent Peptide Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Other medically indicated vaccinations, provided they are administered at least 2&#xD;
             weeks before or after any study injection.&#xD;
&#xD;
          -  Alcohol use limited to 1 oz per day of 100 proof.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection without evidence of AIDS.&#xD;
&#xD;
          -  CD4 count &gt; 500 cells/mm3.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Current evidence of underlying lung or liver disease.&#xD;
&#xD;
          -  Suspected or diagnosed allergy to any vaccine component.&#xD;
&#xD;
          -  Medical contraindication to protocol participation.&#xD;
&#xD;
          -  Undergoing allergy skin testing or desensitization.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral therapy (unless clinically indicated and with approval of&#xD;
             investigator).&#xD;
&#xD;
          -  Immunosuppressive or immunomodulatory therapy.&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory agents (except short-term therapy for acute&#xD;
             conditions).&#xD;
&#xD;
          -  Drugs with known hepatotoxicity.&#xD;
&#xD;
          -  Alcohol intake &gt; 1 oz per day of 100 proof.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of underlying lung disease.&#xD;
&#xD;
          -  Abnormal chest radiograph within 2 weeks prior to first vaccine injection.&#xD;
&#xD;
          -  History of underlying liver disease.&#xD;
&#xD;
          -  Abnormal hepatitis B surface antigen or hepatitis C antibody test within 2 weeks prior&#xD;
             to first vaccine injection.&#xD;
&#xD;
          -  Abnormal liver function tests within 30 days prior to study entry.&#xD;
&#xD;
          -  Evidence of uveitis by slit lamp exam within 2 weeks prior to study entry.&#xD;
&#xD;
          -  Anergic as evidenced by negative skin test responses to all three antigens in a panel&#xD;
             consisting of tetanus toxoid, mumps, and Candida albicans, within 6 weeks prior to&#xD;
             first vaccine injection.&#xD;
&#xD;
          -  Prior participation on an HIV vaccine trial.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within the past 3 months:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Immunosuppressive drugs.&#xD;
&#xD;
          -  Alpha interferon or any immunomodulatory drugs.&#xD;
&#xD;
          -  Any investigational HIV drugs or therapies. Current alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartlett JA</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Tacket CO</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Virani-Ketter N</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS. 1998 Jul 30;12(11):1291-300. doi: 10.1097/00002030-199811000-00010.</citation>
    <PMID>9708408</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

